MTOR and acute lymphoblastic leukemia: mTOR inhibitors have shown promise in preclinical models of ALL through direct inhibition of tumour cell growth and reversal of glucocorticoid resistance and have demonstrated in vitro synergy with dexamethasone (Ref.